219 related articles for article (PubMed ID: 38199451)
1. Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.
Kamath D; Iwakuma T; Bossmann SH
Nanomedicine; 2024 Feb; 56():102732. PubMed ID: 38199451
[TBL] [Abstract][Full Text] [Related]
2. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
5. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.
Zhang S; Carlsen L; Hernandez Borrero L; Seyhan AA; Tian X; El-Deiry WS
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454137
[No Abstract] [Full Text] [Related]
6. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
[TBL] [Abstract][Full Text] [Related]
7. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
8. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
10. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
Kim E; Giese A; Deppert W
Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 in Cancer Progression and Targeted Therapies.
Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
Front Oncol; 2020; 10():595187. PubMed ID: 33240819
[No Abstract] [Full Text] [Related]
12. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A; Padellan M; Marchenko N
Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
[TBL] [Abstract][Full Text] [Related]
14. Targeting mutant p53 for cancer therapy: direct and indirect strategies.
Hu J; Cao J; Topatana W; Juengpanich S; Li S; Zhang B; Shen J; Cai L; Cai X; Chen M
J Hematol Oncol; 2021 Sep; 14(1):157. PubMed ID: 34583722
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
Chen X; Zhang T; Su W; Dou Z; Zhao D; Jin X; Lei H; Wang J; Xie X; Cheng B; Li Q; Zhang H; Di C
Cell Death Dis; 2022 Nov; 13(11):974. PubMed ID: 36400749
[TBL] [Abstract][Full Text] [Related]
16. Degradation of mutant p53H175 protein by Zn(II) through autophagy.
Garufi A; Pucci D; D'Orazi V; Cirone M; Bossi G; Avantaggiati ML; D'Orazi G
Cell Death Dis; 2014 May; 5(5):e1271. PubMed ID: 24874727
[TBL] [Abstract][Full Text] [Related]
17. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
Ubertini V; Norelli G; D'Arcangelo D; Gurtner A; Cesareo E; Baldari S; Gentileschi MP; Piaggio G; Nisticò P; Soddu S; Facchiano A; Bossi G
Oncogene; 2015 May; 34(19):2493-504. PubMed ID: 24998848
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
20. Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials.
Nishikawa S; Iwakuma T
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]